Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$11.59 +5.6%	$11.87	$8.04 ▼ $45.00	$314.33M	2.36	450,223 shs	695,927 shs
BKD Brookdale Senior Living	$6.85 +0.1%	$6.10	$4.45 ▼ $8.12	$1.60B	0.83	2.38 million shs	2.08 million shs
FATE Fate Therapeutics	$1.07 +2.9%	$1.01	$0.66 ▼ $5.92	$122.63M	2.32	2.24 million shs	2.04 million shs
SHCR Sharecare	$1.43	$1.43	$0.48 ▼ $1.44	$531.79M	0.51	2.55 million shs	N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	-14.42%	+13.20%	-31.84%	-59.72%
BKD Brookdale Senior Living	0.00%	+4.39%	+20.35%	+52.60%	-2.41%
FATE Fate Therapeutics	0.00%	-20.61%	-1.89%	-16.80%	-74.51%
SHCR Sharecare	0.00%	0.00%	0.00%	0.00%	+85.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.8611 of 5 stars	4.6	0.0	0.0	0.0	2.6	2.5	0.6
BKD Brookdale Senior Living	3.6457 of 5 stars	2.2	5.0	0.0	4.9	2.7	0.0	0.6
FATE Fate Therapeutics	3.7532 of 5 stars	3.1	2.0	0.0	4.7	2.2	1.7	0.6
SHCR Sharecare	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.13	Buy	$59.20	410.79% Upside
BKD Brookdale Senior Living	2.40	Hold	$7.70	12.49% Upside
FATE Fate Therapeutics	2.14	Hold	$4.60	329.91% Upside
SHCR Sharecare	2.00	Hold	$1.43	N/A

Current Analyst Ratings Breakdown

Latest BKD, FATE, ARCT, and SHCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	BKD Brookdale Senior Living	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
4/16/2025	BKD Brookdale Senior Living	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $7.50
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/10/2025	BKD Brookdale Senior Living	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
4/1/2025	BKD Brookdale Senior Living	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$7.00
3/12/2025	BKD Brookdale Senior Living	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
3/10/2025	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
3/10/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $68.00
3/7/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$63.00 ➝ $60.00
3/7/2025	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/7/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$58.00 ➝ $50.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$138.39M	2.27	N/A	N/A	$10.42 per share	1.11
BKD Brookdale Senior Living	$3.16B	0.51	$1.05 per share	6.50	$1.07 per share	6.40
FATE Fate Therapeutics	$13.63M	9.00	N/A	N/A	$3.74 per share	0.29
SHCR Sharecare	$445.25M	1.19	N/A	N/A	$1.22 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$3.01	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	5/12/2025 (Estimated)
BKD Brookdale Senior Living	-$201.93M	-$1.04	N/A	N/A	N/A	-6.46%	-65.92%	-3.47%	N/A
FATE Fate Therapeutics	-$160.93M	-$1.64	N/A	N/A	N/A	-1,325.43%	-45.88%	-33.95%	N/A
SHCR Sharecare	-$128.50M	-$0.39	N/A	N/A	N/A	-33.64%	-22.81%	-15.96%	N/A

Latest BKD, FATE, ARCT, and SHCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.10	-$0.52	+$0.58	-$0.52	$25.64 million	N/A
5/6/2025	Q1 2025	BKD Brookdale Senior Living	-$0.11	-$0.11	N/A	-$0.28	$816.16 million	N/A
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
3/5/2025	Q4 2024	FATE Fate Therapeutics	-$0.44	-$0.31	+$0.13	-$0.44	$1.57 million	$1.86 million
2/18/2025	Q4 2024	BKD Brookdale Senior Living	-$0.16	-$0.37	-$0.21	-$0.37	$781.78 million	$780.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	6.17%	N/A	N/A	N/A
BKD Brookdale Senior Living	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
SHCR Sharecare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.76	4.76
BKD Brookdale Senior Living	20.05	0.88	0.88
FATE Fate Therapeutics	N/A	8.29	8.29
SHCR Sharecare	N/A	2.02	2.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
BKD Brookdale Senior Living	N/A
FATE Fate Therapeutics	97.54%
SHCR Sharecare	35.08%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
BKD Brookdale Senior Living	1.80%
FATE Fate Therapeutics	5.00%
SHCR Sharecare	30.61%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
BKD Brookdale Senior Living	36,000	234.35 million	196.59 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.20 million	Optionable
SHCR Sharecare	3,352	371.88 million	258.05 million	Optionable

BKD, FATE, ARCT, and SHCR Headlines

Recent News About These Companies

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sharecare Inc. (SHCR) And Encourages Stockholders to Reach Out

May 11 at 10:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sharecare Inc. (SHCR) And Encourages Stockholders to Connect

May 8, 2025 | accessnewswire.com

Sharecare Inc. (SHCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 6, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Sharecare Inc. (SHCR) Shareholders to Inquire about Securities Investigation

May 4, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sharecare Inc. (SHCR) And Encourages Shareholders to Connect

May 1, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sharecare Inc. (SHCR) And Encourages Shareholders to Reach Out

April 29, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sharecare Inc. (SHCR) and Encourages Investors to Learn More About the Investigation

April 24, 2025 | accessnewswire.com

Sharecare Inc. (SHCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

April 22, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sharecare Inc. (SHCR) And Encourages Investors to Connect

April 20, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Sharecare Inc. (SHCR) Stockholders to Inquire about Securities Investigation

April 17, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Sharecare Inc. (SHCR) Investors to Inquire about Securities Investigation

April 15, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sharecare Inc. (SHCR) And Encourages Investors to Reach Out

April 13, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sharecare Inc. (SHCR) And Encourages Stockholders to Reach Out

April 10, 2025 | accessnewswire.com

Sharecare Inc. (SHCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

April 6, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sharecare Inc. (SHCR) And Encourages Shareholders to Reach Out

April 3, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sharecare Inc. (SHCR) and Encourages Shareholders to Learn More About the Investigation

April 1, 2025 | accessnewswire.com

Sharecare Inc. (SHCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

March 30, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sharecare Inc. (SHCR) And Encourages Investors to Connect

March 25, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sharecare Inc. (SHCR) and Encourages Investors to Learn More About the Investigation

March 20, 2025 | accessnewswire.com

Sharecare Inc. (SHCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

March 18, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKD, FATE, ARCT, and SHCR Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$11.59 +0.61 (+5.56%)

Closing price 04:00 PM Eastern

Extended Trading

$12.22 +0.63 (+5.39%)

As of 07:25 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Brookdale Senior Living NYSE:BKD

$6.84 +0.01 (+0.07%)

Closing price 03:59 PM Eastern

Extended Trading

$6.84 -0.01 (-0.13%)

As of 08:00 PM Eastern

Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.

Fate Therapeutics NASDAQ:FATE

$1.07 +0.03 (+2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 +0.10 (+9.25%)

As of 08:00 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Sharecare NASDAQ:SHCR

Sharecare, Inc. operates as a digital healthcare platform company. Its Sharecare platform connects people, patients, providers, employers, health plans, government organizations, and communities that optimize individual and population-wide well-being. The company offers enterprise solutions based on a software-as-a-service model that allows enterprise clients to message, motivate, and manage their populations, as well as measure their population progress; a suite of data and information-driven solutions; and life sciences solutions, which provides members with personalized information, programs, and resources to improve their health and well-being. It also operates RealAge, a platform for health assessment to assess behaviors and existing conditions of its members and provide metric for their physical health. In addition, the company provides secure, automated release of information, audit, and business consulting services to streamline the medical records process for medical facilities. It sells its solutions through direct sales organization and partner relationships. Sharecare, Inc. was founded in 2009 and is headquartered in Atlanta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time